Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Miceli

Showing results (31-40 of 94) with videos related to

Pageof 10
Sort By:
Neurology|January 12, 2007
Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson diseaseS Goldwurm, M Zini, L Mariani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 16, 2005
Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic processR Demicheli, R Miceli, A Moliterni, et al.
Annals of Surgical Oncology|July 31, 2012
Clinical, pathological and surgical characteristics of duodenal gastrointestinal stromal tumor and their influence on survival: a multi-center studyC Colombo, U Ronellenfitsch, Z Yuxin, et al.
Breast Cancer Research and Treatment|June 1, 1995
Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer. A pilot study by the I.T.M.O. Group. Italian Trials in Medical OncologyA Di Leo, L Ferrari, E Bajetta, et al.
Angiogenesis|January 1, 1997
Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: prognostic implicationsM Toi, M Gion, E Biganzoli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2013
Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trialG Procopio, E Verzoni, S Bracarda, et al.
British Journal of Cancer|March 31, 2011
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trialG Procopio, E Verzoni, S Bracarda, et al.
Anticancer Research|January 12, 2000
Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancerP Foa, M Fornier, R Miceli, et al.
The British Journal of Surgery|June 5, 2015
Long-term morbidity after multivisceral resection for retroperitoneal sarcomaD Callegaro, R Miceli, C Brunelli, et al.
The International Journal of Biological Markers|January 11, 2003
Serum levels of tartrate-resistant acid phosphatase-5b in breast cancer patients treated with pamidronateA Martinetti, E Seregni, C Ripamonti, et al.
Pageof 10

Showing results (31-40 of 94) with videos related to

Sort By:
Pageof 10
Neurology|January 12, 2007
Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson diseaseS Goldwurm, M Zini, L Mariani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 16, 2005
Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic processR Demicheli, R Miceli, A Moliterni, et al.
Annals of Surgical Oncology|July 31, 2012
Clinical, pathological and surgical characteristics of duodenal gastrointestinal stromal tumor and their influence on survival: a multi-center studyC Colombo, U Ronellenfitsch, Z Yuxin, et al.
Breast Cancer Research and Treatment|June 1, 1995
Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer. A pilot study by the I.T.M.O. Group. Italian Trials in Medical OncologyA Di Leo, L Ferrari, E Bajetta, et al.
Angiogenesis|January 1, 1997
Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: prognostic implicationsM Toi, M Gion, E Biganzoli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2013
Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trialG Procopio, E Verzoni, S Bracarda, et al.
British Journal of Cancer|March 31, 2011
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trialG Procopio, E Verzoni, S Bracarda, et al.
Anticancer Research|January 12, 2000
Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancerP Foa, M Fornier, R Miceli, et al.
The British Journal of Surgery|June 5, 2015
Long-term morbidity after multivisceral resection for retroperitoneal sarcomaD Callegaro, R Miceli, C Brunelli, et al.
The International Journal of Biological Markers|January 11, 2003
Serum levels of tartrate-resistant acid phosphatase-5b in breast cancer patients treated with pamidronateA Martinetti, E Seregni, C Ripamonti, et al.
Pageof 10